Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8N5Z5
UPID:
KCD17_HUMAN
Alternative names:
-
Alternative UPACC:
Q8N5Z5; B0QYA9; B0QYB0; O95517
Background:
BTB/POZ domain-containing protein KCTD17 plays a pivotal role in ciliogenesis by acting as a substrate-adapter for CUL3-RING ubiquitin ligase complexes, facilitating the ubiquitination and proteasomal degradation of TCHP, a negative regulator of ciliogenesis. Additionally, it may influence endoplasmic reticulum calcium ion homeostasis, highlighting its multifunctional nature.
Therapeutic significance:
Linked to Dystonia 26, myoclonic, a disorder characterized by involuntary muscle contractions and abnormal postures, KCTD17's involvement suggests potential therapeutic targets. Understanding the role of BTB/POZ domain-containing protein KCTD17 could open doors to potential therapeutic strategies.